公司资料
Selecta 股价、新闻与催化剂
- 股票代码:
- SELB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for SELB.
公司概览
业务概览
Selecta Biosciences was a biotechnology company focused on immune tolerance and engineered nanoparticles before becoming a historical ticker. Its story centered on using immunology science to create more precise biologic therapies.
所在地与行业分类
Selecta was headquartered in the United States and listed on NASDAQ. It sat in platform biotechnology and immunology.
商业模式特征
The company depended on clinical data, translational validation, and capital support. Investors historically watched proof-of-concept and strategic development.
生物医药行业定位
Selecta belongs to the historical immunology-platform bucket. It was a science-heavy small-cap name where valuation depended on whether the platform could truly differentiate.
未来催化剂
- Selecta’s catalysts are SEL-212 and the gout / immunology program, plus any strategic update that clarifies the company’s future. The company still needs a cleaner clinical or corporate path.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。